摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

spiro[bicyclo[3.3.1]nonane-3,2'-[1,3]dioxolan]-7-one | 66077-97-2

中文名称
——
中文别名
——
英文名称
spiro[bicyclo[3.3.1]nonane-3,2'-[1,3]dioxolan]-7-one
英文别名
7,7-(ethylenedioxy)bicyclo[3.3.1]nonan-3-one;7,7-ethylenedioxybicyclo[3.3.1]nonan-3-one;Spiro[bicyclo[3.3.1]nonane-3,2'-[1,3]dioxolane]-7-one;spiro[1,3-dioxolane-2,7'-bicyclo[3.3.1]nonane]-3'-one
spiro[bicyclo[3.3.1]nonane-3,2'-[1,3]dioxolan]-7-one化学式
CAS
66077-97-2
化学式
C11H16O3
mdl
——
分子量
196.246
InChiKey
LNBKOECPIAUOMQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    79-80 °C(Solv: ligroine (8032-32-4))
  • 沸点:
    322.4±42.0 °C(Predicted)
  • 密度:
    1.18±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • 一种化合物及其用途
    申请人:成都海博锐药业有限公司
    公开号:CN109575022B
    公开(公告)日:2021-09-21
    本发明提供了一种新化合物,该化合物对氧化还原酶吲哚胺2,3‑双加氧酶(IDO)有一定的抑制活性,或可用于治疗与之相关的疾病,包括癌症及免疫相关疾病的用途。
  • Highly Enantioselective Organocatalytic Oxidative Kinetic Resolution of Secondary Alcohols Using Chirally Modified AZADOs
    作者:Masaki Tomizawa、Masatoshi Shibuya、Yoshiharu Iwabuchi
    DOI:10.1021/ol900441f
    日期:2009.4.16
    A highly enantioselective organocatalytic oxidative kinetic resolution (OKR) of racemic secondary alcohols has been accomplished using asymmetric organocatalysis. A panel of chirally modified 2-azaadamantane N-oxyls (AZADOs) exhibit superior catalytic activity and high enantioselectivity, allowing us to obtain optically active secondary alcohols with a krel value up to 82.2.
    外消旋仲醇的高度对映选择性有机催化氧化动力学拆分(OKR)已使用不对称有机催化实现。一组手性改性的2-氮杂金刚烷N-氧基(AZADOs)表现出优异的催化活性和高对映选择性,使我们能够获得k rel值高达82.2的旋光仲醇。
  • Alternative syntheses of bridgehead polycyclic 1,2-diamines and 2-aminoalcohols from di- and mono-oximes of some bicyclic diketones: Highly improved synthesis of tricyclo[3.3.1.03,7]nonane-3,7-diamine
    作者:Pelayo Camps、Diego Muñoz-Torrero
    DOI:10.1016/s0040-4039(00)76863-8
    日期:1994.5
    Bridgehead polycyclic 1,2-diamines 4a and 4b have been obtained from dioximes 2a and 2b, respectively, by two alternative procedures: a) m-chloroperbenzoic acid oxidative coupling to 3a and 3b, followed by reduction with aluminum amalgam, and b) reductive coupling with aluminum amalgam. Similarly, the related 2-aminoalcohols 9a and 9b have been obtained from the corresponding monooximes 7a and 7b.
    通过两种替代方法分别从二肟2a和2b获得桥头多环1,2-二胺4a和4b:a)间氯过苯甲酸氧化偶联至3a和3b,然后用铝汞齐还原,和b)还原性与铝汞合金耦合。类似地,已经从相应的单肟7a和7b获得了相关的2-氨基醇9a和9b。
  • 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE
    申请人:GRACZYK Piotr Pawel
    公开号:US20100069354A1
    公开(公告)日:2010-03-18
    The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
    本发明提供了公式(I)的化合物;或其药学上可接受的盐,使用公式(I)的化合物或其药学上可接受的盐来抑制c-Jun N末端激酶(JNK)活性,并用于医药学,特别是用于治疗神经退行性疾病、炎症性疾病和/或自身免疫性疾病。本发明还提供了制备所述公式(I)的化合物或其药学上可接受的盐的方法和含有它们的组合物。
  • 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
    申请人:Eisai R&D Management Co., Ltd.
    公开号:US08178552B2
    公开(公告)日:2012-05-15
    The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
    本发明提供化合物(I)的公式;或其药学上可接受的盐,化合物(I)或其药学上可接受的盐在抑制c-Jun N-末端激酶(JNK)活性方面的用途,以及在医学上特别是治疗神经退行性疾病、炎症性疾病和/或自身免疫性疾病方面的用途。本发明还提供了制备上述化合物(I)或其药学上可接受的盐的方法和含有它们的组合物。
查看更多